Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010
The meta-analysis by Ray et al1(p1030) found that statins therapy has “no benefit on all-cause mortality in high-risk primary prevention population.” Because of the importance of this study to clinicians and policy makers, its results and interpretation should be carefully examined.
In summarizing the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) study,2 the authors calculated a risk ratio of 0.98, while the original publication reported a risk ratio of 0.87. This change alone may have biased against finding a statistically significant benefit for statin use.
Chodick G, Shalev V. Statins and All-Cause Mortality in High-Risk Primary Prevention: A Second Look at the Results. Arch Intern Med. 2010;170(22):2041–2042. doi:10.1001/archinternmed.2010.456
Customize your JAMA Network experience by selecting one or more topics from the list below.